RedHill Biopharma Ltd. (RDHL)
After hours:
| Previous close | 0.3805 |
| Open | 0.3766 |
| Bid | 0.2940 x 200 |
| Ask | 0.4937 x 200 |
| Day's range | 0.3740 - 0.4250 |
| 52-week range | 0.2570 - 3.2800 |
| Volume | |
| Avg. volume | 279,932 |
| Market cap | 12.645M |
| Beta (5Y monthly) | 3.63 |
| PE ratio (TTM) | 0.10 |
| EPS (TTM) | 4.0000 |
| Earnings date | 29 Jul 2024 - 04 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireRedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC (the "Agreement"). As a result of the Agreement, RedHill received approximately $9.9 million in cash and gained full control over an additional $0.74 million currently held in a restricted account, leading to an increase of approximately $12.2 million in
- PR Newswire
RedHill Biopharma Terminates License Agreement for Aemcolo®
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual decision with Cosmo Technologies Ltd. ("Cosmo") to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea (the "License Agreement"). The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024.
- PR Newswire
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent notice of allowance for opaganib[4] in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response, providing protection for opaganib's potential use with a range of approved and in-development immune checkpoint inhibitors (ICIs) across a growing range of indications through 2040. The patent wi
